You just read:

Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms

News provided by

ReportBuyer

Oct 26, 2016, 20:52 ET